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Abstract
Background: Glycation of serum proteins has been proposed as an important mechanism of complications of
diabetes but whether there are differences in glycation of different serum proteins and whether it has any correlation
with development of microvascular complications has not been studied in depth. This study aimed to assess level of
serum fructosamine, glycated albumin and glycated β-lipoprotein in type 2 diabetes mellitus patients with and without
microvascular complications and to find out their correlation with diabetes complications.
Methods: Case–control study involving 150 individuals at a tertiary care hospital in western India. Fifty participants
were healthy controls (group 1), 50 were type 2 diabetes patients without any evident microvascular complication
(group 2) and 50 were type 2 diabetes patients with one or more microvascular complications (group 3). Serum
fructosamine, FBS, PP2BS and other biochemical parameters were measured. Glycated albumin and glycated β-lipoprotein
were measured by agarose gel electrophoresis followed by NBT staining. Unpaired t-test was used to find out significance
of difference between two groups and correlation coefficient to find out statistical correlation between two variables.
Results: Type 2 diabetes patients with one or more microvascular complications had poor glycemic control as indicated
by markers of short and mid-term glycemia. Differences between the groups for fructosamine, glycated albumin and
glycated β-lipoprotein were significant (p < 0.001). Glycated albumin correlated with FBS, PP2BS and fructosamine in all
diabetic patients (group 2 and 3) whereas glycated β-lipoprotein correlated with these parameters only in group 3 and it
was markedly elevated in group 3.
Conclusion: Serum glycated β-lipoprotein was disproportionately elevated compared to fructosamine and glycated
albumin in diabetes patients with microvascular complications (group 3) and it correlated with rest of glycemic markers
only in this group. Glycated β-lipoprotein might help in identifying diabetic individuals at high future risk of developing
microvascular complications.
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Background
Hyperglycemia not only defines diabetes but it is also
the cause of its most characteristic symptoms and long-
term complications. Non-enzymatic glycation changes
the structure and function of many soluble and insoluble
proteins and it is probably the most important pathogenic
mechanism amongst several proposed mechanisms.
Because cells and their extracellular matrix share a dy-
namic relationship, modulation of matrix components
by glycation leads to altered cell behaviour, including
changes in cell spreading, phosphorylation of key intracel-
lular signalling molecules, and expression of extracellular
matrix proteins and their modulators. Accumulation of
glycation products and the accompanying structural extra-
cellular matrix modifications correlate with the develop-
ment of complications of diabetes. These changes in tissue
structure and function are slow and cumulative, producing
a long time lag between the start of diabetes and the onset
and progression of the complications [1]. Because the
development of complications is linked to the accumula-
tion of glycation adducts in tissue proteins, any analytical
method that serves as an index of the extent of glycation
can be used to guide therapy in diabetes. Amongst the
various markers of glycemic control, glycated hemoglobin
has now been established as a gold-standard long-term
glycemic control index [2].
Glucose molecules are joined to protein molecules
through glycation to form stable ketoamines, or fruc-
tosamines. It is a nonenzymatic mechanism involving
a labile Schiff base intermediate and the Amadori
rearrangement. The amount of fructosamine in serum
is increased in diabetes mellitus owing to the abnor-
mally high concentration of sugar in blood. The con-
centration of fructosamine in serum thus reflects the
degree of glycaemic control attained by the diabetic
patient over last 2–3 weeks and is useful in monitoring the
effectiveness of therapy in diabetes over a period of several
weeks, in a manner analogous to the determination of
glycated hemoglobin [3]. Similar is the case with other
glycated serum proteins depending on their half-lives,
most widely studied and used of those is glycated albumin
which is an indicator of glycaemic status over preceding
2–3 weeks. Due to 3–5 day circulating half-life of LDL,
glycated LDL level reflects mean glycemia over the pre-
ceding week [4].
With availability of rapidly advancing information
regarding molecular mechanisms, their inter-relations
and their role in diseases, glycated serum proteins are
coming to lime-light again. Glycated albumin, glycated
LDL and glycated HDL have been found to be implicated
in diabetic vascular diseases [5]. More and more studies
are being conducted which assess these glycated proteins
on molecular bases and, as a result, more and more new
associations are being noticed. The results of the initial
studies and also conclusions from other studies that rate of
glycation of individual proteins shows biological variability
from person to person at a same blood glucose level; have
put glycated serum proteins beyond the markers of gly-
cemia. Individual proteins are being measured and their
associations are being sought for. This might lead to
more and more markers coming from research setting
to field level and some of these might even be specific
for predicting a particular diabetic complication [5–7].
The study was undertaken to assess level of serum
fructosamine, glycated albumin and glycated β-lipoprotein
in type 2 diabetes mellitus patients with and without micro-
vascular complications and to find out their correlation
with the complications. Serum fructosamine was measured
as an indicator of serum total glycated proteins and as a
marker of short to medium term glycemic control.
Methods
Study design and subjects
This was a hospital based case–control study consisting
of three groups and total 150 participants. Group 1 (con-
trol group, n = 50) consisted of randomly selected age
and sex matched non-diabetic subjects. They were free
from any ailment which could affect the parameters
under study (no clinical history or investigative result
showing involvement of any organ system). They were
selected from medical and paramedical staff, attendants
of patients and persons coming to hospital for fitness
purpose. Group 2 (type 2 diabetes mellitus patients with-
out any microvascular complications, n = 50) consisted
of those with duration of diabetes 3 years or more, on
life style modifications and oral anti-diabetic drugs and
free from clinical or laboratory evidence of any micro-
vascular complication of diabetes mellitus. Group 3 (type
2 diabetes mellitus patients with microvascular compli-
cations, n = 50) of those with duration of diabetes 3 years
or more, on life style modifications, oral anti-diabetic drugs,
insulin or combination of all three and diagnosed as having
one or more microvascular complication of diabetes
mellitus; either diabetic neuropathy (peripheral neur-
opathy diagnosed by 10 g monofilament and reduced
vibration perception using 128 Hz tuning fork), diabetic
nephropathy (urine albumin ≥30 μg/mg of creatinine
with normal urine microscopy and not a known case of
any other kidney disease) or diabetic retinopathy (diagnosed
by direct ophthalmoscopy after mydriasis). Consecutive
patients attending the medical outpatient department were
enrolled in groups 2 and 3 unless they met any of the exclu-
sion criterions.
Patients with type 1 diabetes mellitus, pregnant
females and patients with diseases unrelated to diabetes
which might significantly alter serum protein profile e.g.
hepatic diseases, hematological malignancy, chronic infec-
tions and inflammations like tuberculosis, sarcoidosis,
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rheumatological diseases, infectious mononucleosis, AIDS
were excluded from the study.
Data collection and sample collection
Objectives of the study were explained to all subjects
eligible for this study. Informed written consent of all
the subjects was obtained for voluntary participation in
study group, sample collection and for data utilisation
for the purpose of publication. Data were recorded in a
questionnaire designed for the study and it included
socio-demographic data, presenting complains, detailed
diabetes history including treatment and complications,
history of other ailments, past, personal and family histories
as well as findings of a thorough physical examination. For
each subject, overnight fasting blood sample was collected
in a fluoride vacutainer for FBS and in a plain vacutainer
for other biochemical parameters. Urine sample was
collected in universal container for urine creatinine and
urine protein estimation. Post prandial (2 h) sample
was collected in a fluoride vacutainer for PP2BS estima-
tion. Serum and plasma were separated within an hour of
collection and stored at 2 to 8 °C temperature till analyses
were performed. Electrophoresis was performed within
5 days whereas all the other parameters were estimated on
the same day.
Sample analysis
FBS and PP2BS were estimated by Glucose Oxidase-
Peroxidase (GOD-POD) enzymatic end point method.
Serum fructosamine was estimated by NBT colorimetric
kinetic assay. Serum Creatinine concentration was mea-
sured by modified Jaffe’s kinetic method. Serum total chol-
esterol was estimated by Cholesterol Oxidase-Peroxidase
(CHOD-PAP) enzymatic end point method. Serum LDL
cholesterol was measured by direct enzymatic method.
Urinary creatinine was estimated by modified Jaffe’s kinetic
method, urinary protein was measured by Pyrogallol red
end point method and urinary protein/creatinine ratio was
calculated. All biochemical investigations were performed
on a fully automated analyzer.
Serum glycated β-lipoprotein was measured by agarose
gel film electrophoresis at pH 8.6 followed by colour
development with nitro-blue tetrazolium (NBT) by a
modification of staining method adapted from Kunio
Kobayashi et al. [8]. Dried and compressed electrophoresis
plate was immersed for 20 h in glycated protein colour de-
velopment reagent (5 mmol/l NBT in 50 mmol/l sodium
carbonate buffer pH 10.3) at room temperature followed by
two washes of stop solution (0.3% citric acid). NBT stained
blue bands on the glycated protein film were scanned at
540 nm (Olympus glass filter plate) using a densitometric
scanner (Nikon Super COOLSCAN 9000 ED). Image was
analysed by free electrophoresis image analysis software
GelAnalyzer 2010a. Proportions (%) of glycated albumin
and glycated lipoprotein were represented as the percentage
of total area under the scanned profile attributable to
each peak. Concentration (in μmol/l) was calculated by
multiplying percentage with serum fructosamine value.
Staining in β region was considered to represent glyca-
tion of β-lipoproteins. Serum protein (stained with 0.5%
acid blue 29 in 5% acetic acid) and lipoprotein (stained
with 0.05% fat red 7B and 0.05% oil red O in methanol:-
water, 4:1) electrophoresis was performed simultan-
eously for all the samples to aid in quantitation by
comparison of mobility of respective proteins. Run-to-
run reproducibility of the assay of glycated albumin was
Table 1 Comparison of study groups
Group 1 Group 2 Group 3
Number of participants 50 50 50
Sex (M/F) 58/42 54/46 48/52
Average age (years) 47 ± 10 53 ± 9 52 ± 9
Average duration of diabetes mellitus (in year) - 6.3 ± 2.8 8.2 ± 3.8
FBS (mg/dl) 94 ± 11 129 ± 39 188 ± 86
PP2BS (mg/dl) 119 ± 11 184 ± 57 271 ± 109
Serum creatinine (mg/dl) 0.89 ± 0.20 0.96 ± 0.19 1.03 ± 0.29
Serum total protein (gm/dl) 6.8 ± 0.6 6.8 ± 0.5 6.7 ± 0.5
Serum albumin (gm/dl) 4.3 ± 0.3 4.4 ± 0.3 4.3 ± 0.3
Serum total cholesterol (mg/dl) 174 ± 35 177 ± 37 184 ± 43
Serum LDL cholesterol (mg/dl) 121 ± 29 117 ± 27 121 ± 27
Urinary protein/creatinine (mg/g) 11 ± 9 18 ± 8 140 ± 161
Serum fructosamine (μmol/l) 253 ± 24 313 ± 58 395 ± 119
Serum glycated albumin (μmol/l) 136 ± 26 162 ± 42 202 ± 78
Serum glycated β-lipoprotein (μmol/l) 25.2 ± 5.1 32.8 ± 7.8 50.4 ± 11.6
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7.1% and for glycated β-lipoprotein was 7.7% when
tested with a human serum sample with fructosamine
value of 284 μmol/l (n = 10). The assay also performed
satisfactorily when tested for linearity by using a very
high fructosamine value (894 μmol/l) sample and its 1:1
to 1:8 dilutions.
Statistical analysis
Data collected were recorded and analysed statistically
to determine the significance of different parameters by
MedCalc version 12.4. Statistical analysis was done by
using unpaired t-test to find out significance of difference
between two groups and correlation coefficient to find out
statistical correlation between two variables and its signifi-
cance. p value less than 0.05 was considered significant.
Results
Patients having one or more microvascular complica-
tions were having poor glycemic control and large
inter-individual variations as indicated by higher mean
and larger SD values of glycemic indicators in group 3
(Table 1). Prevalence of fructosamine value higher than
upper reference value (285 μmol/l) in group 1 was 2%,
in group 2 was 60% and in group 3 was 92% and differ-
ences between these groups for serum fructosamine,
glycated albumin as well as glycated β-lipoprotein were
statistically significant (Table 2, Figs. 1, 2 and 3). Serum
fructosamine and glycated albumin values correlated
very well with both FBS and PP2BS in groups 2 and 3,
whereas correlation was not observed in group 1 (Table 3).
Glycated albumin showed excellent correlation with
fructosamine across groups (p ≤ 0.0003 in all groups)
and correlation coefficient r was >0.9 in groups 2 and 3
(Table 3). Glycated β-lipoprotein correlated well with
FBS, PP2BS, fructosamine and glycated albumin only in
group 3 (Table 3). Irrespective of the groups, serum gly-
cated albumin showed excellent correlation with serum
fructosamine whereas glycated β-lipoprotein level did
not correlate well with either of fructosamine or gly-
cated albumin, correlation with glycated albumin being
particularly poor (Figs. 4, 5 and 6).
Remarkably, glycated β-lipoprotein is specifically ele-
vated in diabetes patients with microvascular complica-
tions (group 3) and it also shows large inter-individual
variation as suggested by the SD value. The rise in mean
glycated β-lipoprotein is disproportionate and not in line
with rise in glycated albumin; as indicated by comparing
the groups (Table 4). In group 3, as compared to group
1, there was 49% more glycated albumin whereas 100%
more glycated β-lipoprotein.
Discussion
Findings in this study go hand in hand with the current
establishments about serum fructosamine. Measurements
of total glycated serum proteins and glycated serum
albumin have been found in various studies, now over three
decades, to correlate well with glycated hemoglobin and
have been suggested as alternative methods for routine
Table 2 Independent sample t-test: serum fructosamine, glycated albumin and glycated β-lipoprotein between study groups
Study
groups
Fructosamine Glycated β-Lipoprotein level Glycated albumin
Test statistic t Two tailed probability Test statistic t Two tailed probability Test statistic t Two tailed probability
1 and 2 6.761 p < 0.0001 5.719 p < 0.0001 3.751 p = 0.0003
2 and 3 4.388 p < 0.0001 8.937 p < 0.0001 3.235 p = 0.0018
1 and 3 8.316 p < 0.0001 14.043 p < 0.0001 5.728 p < 0.0001
Fig. 1 Box-and-Whisker distribution plot of serum fructosamine in
study groups (bars indicate mean)
Fig. 2 Box-and-Whisker distribution plot of serum glycated albumin
in study groups (bars indicate mean)
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monitoring of glycemic control in patients with diabetes
[9]. Additionally, there has been an increased interest to
study these markers during recent past as they are now very
well established as markers of intermediate term glycemia.
There are many reports of intermediate term glycemic
markers having their own role in addition to SMBG and
the well-established ‘gold-standard’ glycemic marker HbA1c
[4]. They have specific utility in glycemic monitoring of ges-
tational diabetes mellitus and other conditions where
HbA1c is not usable due to any reason [10]. These markers
are immensely useful to adjust dosage of medication as they
detect either improving or deteriorating glycemic status
within a span of a week, much before the same changes in
glycated Hb are evident (around four weeks) [3]. Fructosa-
mine and glycated albumin are even being considered as
diagnostic markers of pre-diabetes and diabetes [11, 12].
In contrary to previous beliefs, Kunio Kobayashi et al.
demonstrated that fructosamine level in serum reflects not
only glycation of albumin but also of lipoproteins. They also
found that high concentration of glycated β-lipoprotein in
diabetics is attributable not only to increase in the concen-
tration of β-lipoprotein but also to accelerated glycation of
lipoproteins in diabetics with hyperglycemia [8, 13]. Find-
ings of the present study also suggest the same. T. J. Lyons
et al. and C. M. Jack et al. using different methods found
that, in diabetic patients, increased glycosylation of LDL oc-
curs to an extent which correlates closely with other com-
monly used indices of glycemic control [14, 15]. In addition
to its role in vascular complications, glycated LDL is also a
short term glycemic marker, reflecting glycemia over past 1
week (3 to 5 day circulating half-life) [4, 16].
The most striking feature of this study was disproportion-
ate elevation of glycated β-lipoprotein in diabetes patients
with microvascular complications. The most plausible ex-
planation for disproportionate elevation in glycated LDL is
elevated small dense LDL in diabetes which is more suscep-
tible to glycation than more buoyant LDL [17–20]. The
capacity of glycated LDL for vascular damage is increased
Fig. 3 Box-and-Whisker distribution plot of serum glycated β-
lipoprotein in study groups (bars indicate mean)
Table 3 Correlation of study parameters
Correlation between parameters Group 1 Group 2 Group 3
Serum fructosamine (μmol/l) and FBS (mg/dl) r 0.0749 0.6446 0.7644
p 0.6053 <0.0001 <0.0001
Serum fructosamine (μmol/l) and PP2BS (mg/dl) r −0.1174 0.5254 0.8142
p 0.4168 0.0001 <0.0001
Serum glycated albumin (μmol/l) and FBS (mg/dl) r −0.1182 0.5085 0.7675
p 0.9351 0.0002 <0.0001
Serum glycated albumin (μmol/l) and PP2BS (mg/dl) r −0.1785 0.3956 0.8023
p 0.2149 0.0045 <0.0001
Serum glycated β-lipoprotein (μmol/l) and FBS (mg/dl) r 0.0186 0.3702 0.5915
p 0.8979 0.0081 <0.0001
Serum glycated β-lipoprotein (μmol/l) and PP2BS (mg/dl) r −0.1802 0.4013 0.6240
p 0.2105 0.0039 <0.0001
Serum glycated Albumin (μmol/l) and fructosamine (μmol/l) r 0.4896 0.9133 0.9491
p 0.0003 <0.0001 <0.0001
Serum glycated β-lipoprotein (μmol/l) and fructosamine (μmol/l) r 0.3626 0.3073 0.6661
p 0.0097 0.0300 <0.0001
Serum glycated β-lipoprotein (μmol/l) and glycated albumin (μmol/l) r 0.2152 0.1323 0.5625
p 0.1295 0.3549 <0.0001
r = correlation coefficient, p = probability
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by its tendency to promote oxidation of the apolipoproteins
themselves and the lipids in the particle core, yielding
glycoxidized LDL. In many studies, glycoxidized LDL
has been found to exaggerate cellular responses as previ-
ously mentioned with glycated albumin [6, 21, 22]. Precise
mechanisms underlying why glycated beta-lipoprotein rise
was disproportionate in diabetes patients with micro-
vascular complication compared to those without them
are yet to be understood.
Cellular effects resulting from glycation of LDL has been
linked to both macro- and micro-vascular complications
of diabetes. In vivo modified LDL from diabetic subjects
as well as in vitro glycated LDL have been shown to en-
hance microvascular tone, which could contribute to im-
paired vascular reactivity in diabetes [23]. Studies have
demonstrated that glycation diminishes the uptake and
degradation of LDL by the high affinity LDL receptor,
promotes uptake and metabolism by alternative path-
ways (e.g. monocyte-macrophages that give rise to foam
cells) and decreases the rate of clearance of LDL in vivo [6].
Glycation also alters regulation of hydroxymethylyglutaryl-
CoA reductase and acyl-CoA:cholesterol transferase activ-
ities, and accelerates free radical production and increases
lipid peroxidation, which can enhance LDL atherogenicity
through recognition and internalization of oxidized Apo B
adducts by macrophage scavenger receptors and formation
of foam cells. Macrophage uptake of glycated LDL is
greater than that of control LDL [6, 21]. Glycated LDL has
been shown to induce functional changes in various cell
types including enhancement of chemotactic properties in
monocytes, stimulating migration and proliferation of
smooth muscle cells, and increasing platelet aggregation,
Fig. 4 Correlation of serum fructosamine and glycated albumin (n = 150)
Fig. 5 Correlation of serum fructosamine and glycated β-lipoprotein (n = 150)
Kalaria et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:53 Page 6 of 8
nitric oxide production, and Ca + 2-ATPase activity. Glyca-
tion of LDL increases its interaction with arterial proteo-
glycans and glycated LDL has also been found to trigger
apoptosis of vascular endothelial cells by increasing the
expression of apoptosis promoters [6, 24]. Glycation of
LDL promotes oxidation of lipids and apolipoproteins and
hence increases formation of glyoxidised LDL [25], which
has been shown to enhance the cellular responses even
further [6]. Endothelial dysfunction as a result of all these
factors is closely linked with both micro- and macrovas-
cular disease in diabetes [26]. Heavily oxidised and glycated
LDL have been found to reduce expression of TIMP3 (tis-
sue inhibitor of metalloproteinases 3) which might contrib-
ute to microvascular abnormalities in diabetic retinopathy
[27]. Lyons et al. have demonstrated reduced cell viability
in cultured retinal capillary cells after exposure to in vitro
glycated vs native LDL [28]. Antibodies to oxidised LDL,
glycated LDL and AGE modified LDL as well as the
resulting immune complexes have pro-inflammatory effects
and they increase foam cell formation and hence have been
implicated in microvascular complications as well as ath-
erosclerosis [29]. In DCCT/EDIC cohort (type 1 diabetes),
higher levels of oxidised LDL and AGE-LDL in immune
complexes were associated with higher odds of developing
abnormal albuminuria [30].
Conclusion
Diabetic patients having one or more microvascular
complications had poor glycemic control. Serum fructosa-
mine and glycated albumin showed excellent correlation
with each other across study groups. Moreover, they corre-
lated well with FBS and PP2BS in diabetic patients and thus
remain as important markers of short to medium term
glycemic control. Strikingly, glycated β-lipoprotein was
markedly increased in type 2 diabetes patients with
microvascular complications and the rise was dispro-
portionate to that in glycated albumin. This indirectly
indicates that glycated β-lipoprotein might help in iden-
tifying diabetic individuals at high risk of developing
microvascular complication in future; and also lower
LDL targets might be beneficial in diabetic individuals
especially those having microvascular complications.
Glycated β-lipoprotein correlated well with FBS, PP2BS,
fructosamine and glycated albumin only in diabetes pa-
tients with one or more microvascular complication
and not in the other two groups. As more and more
such data becomes available and more studies of mo-
lecular mechanisms emerge, glycosylation of lipopro-
teins is likely to emerge as a very important mechanism
of microvascular complication of diabetes.
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